PLUR Stock Overview
Pluri Inc., a biotechnology company, engages in the development of placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
Pluri Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$4.90 |
52 Week High | US$8.56 |
52 Week Low | US$3.45 |
Beta | 1.51 |
1 Month Change | -39.95% |
3 Month Change | -23.72% |
1 Year Change | -36.86% |
3 Year Change | -85.82% |
5 Year Change | -90.39% |
Change since IPO | -99.69% |
Recent News & Updates
Recent updates
Pluri gains as PROTO project receives €7.5M EU grant
Sep 06Pluristem Therapeutics renames as Pluri
Jul 25Pluristem Therapeutics (NASDAQ:PSTI) Has Debt But No Earnings; Should You Worry?
Dec 04We Think Pluristem Therapeutics (NASDAQ:PSTI) Needs To Drive Business Growth Carefully
Aug 18What Is The Ownership Structure Like For Pluristem Therapeutics Inc. (NASDAQ:PSTI)?
Mar 15We're Hopeful That Pluristem Therapeutics (NASDAQ:PSTI) Will Use Its Cash Wisely
Feb 08Pluristem Therapeutics launches $30M registered direct offering
Feb 02Have Insiders Been Buying Pluristem Therapeutics Inc. (NASDAQ:PSTI) Shares?
Jan 04Pluristem expands COVID-19 program in Mexico
Dec 29Pluristem - Moment Of Truth
Dec 08Market Sentiment Around Loss-Making Pluristem Therapeutics Inc. (NASDAQ:PSTI)
Nov 30Shareholder Returns
PLUR | US Biotechs | US Market | |
---|---|---|---|
7D | -3.0% | 0.4% | 1.0% |
1Y | -36.9% | 0.9% | 21.9% |
Price Volatility
PLUR volatility | |
---|---|
PLUR Average Weekly Movement | 11.7% |
Biotechs Industry Average Movement | 11.6% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 16.8% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: PLUR's share price has been volatile over the past 3 months.
Volatility Over Time: PLUR's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2001 | 129 | Yaky Yanay | www.pluri-biotech.com |
Pluri Inc., a biotechnology company, engages in the development of placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions. It operates in the field of regenerative medicine, food-tech, and biologics and focuses on establishing partnerships that leverage its 3D cell-based technology to additional industries that require mass cell production. The company’s development pipeline includes PLX-PAD, is composed of maternal mesenchymal stromal cells originating from the placenta that is currently under phase III study for orthopedic, phase II study for COVID-19, and phase I/II clinical study for Steroid-Refractory cGVHD indications; and PLX-R18, is composed of fetal MSC like cells originating from the placenta that is currently under phase I study for HCT and pilot study for ARS indications.
Pluri Inc. Fundamentals Summary
PLUR fundamental statistics | |
---|---|
Market cap | US$25.53m |
Earnings (TTM) | -US$23.95m |
Revenue (TTM) | US$357.00k |
71.5x
P/S Ratio-1.1x
P/E RatioIs PLUR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
PLUR income statement (TTM) | |
---|---|
Revenue | US$357.00k |
Cost of Revenue | US$9.00k |
Gross Profit | US$348.00k |
Other Expenses | US$24.30m |
Earnings | -US$23.95m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -4.60 |
Gross Margin | 97.48% |
Net Profit Margin | -6,708.40% |
Debt/Equity Ratio | 368.8% |
How did PLUR perform over the long term?
See historical performance and comparison